Iranian Firm Produces Special Drug for Patients with Pulmonary Fibrosis

Maryam Navabakhsh from the medical department of a pharmaceutical company announced the production of the drug Ofenib (Nintedanib) in two doses of 100 and 150 mg, saying, "Ofenib is a specialized drug for pulmonary fibrosis, the production of which is on the agenda of our company and has now entered the market.”

“Ofenib is used specifically for types of pulmonary fibrosis; including pulmonary fibrosis of unknown cause (idiopathic), pulmonary fibrosis associated with autoimmune diseases like systemic scleroderma and other forms of progressive pulmonary fibrosis for which there was previously little hope of treatment or patients were hospitalized in the ICU,” she added.

“Gastrointestinal complications are among the known complications of this drug, and appropriate monitoring and usage protocols must be followed by the treating physicians,” Navabakhsh said.

Nintedanib is an oral medication used for the treatment of idiopathic pulmonary fibrosis and along with other medications for some types of non-small-cell lung cancer.

Common side effects include abdominal pain, vomiting, and diarrhea. It is a small molecule tyrosine-kinase inhibitor, targeting vascular endothelial growth factor receptor, fibroblast growth factor receptor and platelet derived growth factor receptor.

4155/v

Azra Varasteh